FRANKLIN TEMPLETON

# Franklin Future of Health and Wellness UCITS ETF

**IE0003WEWAX4** | **Thematic** | Factsheet as of 30 September 2026

**This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.**

## Investment Overview

To provide exposure to companies that are involved in delivering sustainable products and services related to health and wellness globally. The Fund invests in equities of developed market companies that utilize technology and demonstrate innovation within the healthcare industry as well as companies that are enabling access to care, health, or wellness provision for a wide range of consumers including the elderly.

**Past performance does not predict future returns.**

## Performance Over 3 Years (%)




## Discrete Annual Performance (%)

| | 09/25 09/26 | 09/24 09/25 | 09/23 09/24 | 09/22 09/23 | 09/21 09/22 | 09/20 09/21 | 09/19 09/20 | 09/18 09/19 | 09/17 09/18 | 09/16 09/17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Fund | 8.93 | -3.76 | 22.00 | — | — | — | — | — | — | — |
| Benchmark | 9.04 | -3.63 | 22.11 | — | — | — | — | — | — | — |

## Total Returns (%)

| | Cumulative | | | | | | | Average Annual | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | 1-Mo | 3-Mo | YTD | 1-Yr | 3-Yr | 5-Yr | Inception | 3-Yr | 5-Yr | Inception | Inception Date |
| Fund | -2.86 | 4.27 | 3.43 | 8.93 | 27.90 | — | 18.68 | 8.55 | — | 5.43 | 05/07/2023 |
| Benchmark | -2.84 | 4.32 | 3.48 | 9.04 | 28.31 | — | 19.11 | 8.66 | — | 5.55 | — |

The fund's returns may increase or decrease as a result of changes to foreign exchange rates. All performance data shown is in the fund's base currency. Performance data is based on the net asset value (NAV) of the ETF which may not be the same as the market price of the ETF. Individual investors may realise returns that are different to the NAV performance. **Past performance does not predict future returns.** The actual costs vary depending on the executing custodian. In addition, deposit costs may be incurred which could have a negative effect on the value. Please find out the costs due from the respective price lists from the processing/custodian bank. Changes in exchange rates could have positive or negative effects on this investment. **Please visit https://www.franklintempleton.com/corporate/all-sites for current performance and see the latest prospectus or supplement for further details.** When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates maybe used between the portfolio and its benchmark.

## Fund Overview

| | |
|---|---|
| Umbrella | Franklin Templeton ICAV |
| Fund Base Currency | USD |
| Fund Inception Date | 05/07/2023 |
| Valor Number | 127057322 |
| ISIN | IE0003WEWAX4 |
| Domicile | Ireland |
| UCITS | Yes |
| Product Structure | Physical |
| Replication Methodology | Full Replication |
| Frequency of Index Reconstitution | Semi-Annual |
| Use of Income | Accumulation |
| Fiscal Year End | 30 June |
| Shares Outstanding | 100,000 |
| EU SFDR Category | Article 8 |

## Benchmark(s) and Type

| | |
|---|---|
| Solactive Sustainable Health and Wellness Index-NR | Target |

## Charges

| | |
|---|---|
| Total Expense Ratio | 0.30% |

The charges are the fees the Fund charges to investors to cover the costs of running the Fund. Additional costs, including transaction fees, will also be incurred. These costs are paid out by the Fund, which will impact on the overall return of the Fund. Fund charges will be incurred in multiple currencies, meaning that payments may increase or decrease as a result of currency exchange fluctuations.

## Fund Characteristics

| | Fund | Target |
|---|---|---|
| Total Net Assets (USD) | $2.93 Million | |
| Number of Holdings | 81 | 80 |
| Price to Book | 2.74x | 3.35x |
| Price to Earnings (12-Month Trailing) | 22.07x | 22.40x |
| Return on Equity | 18.03% | 18.01% |
| Dividend Yield | 1.59% | 1.58% |
| Standard Deviation (3 Yr) | 13.49% | 13.48% |

## Top Equity Issuers (% of Total)

| | Fund |
|---|---|
| PFIZER INC | 3.80 |
| INTUITIVE SURGICAL INC | 3.73 |
| MERCK & CO INC | 3.62 |
| ABBVIE INC | 3.61 |
| VERTEX PHARMACEUTICALS INC | 3.57 |
| JOHNSON & JOHNSON | 3.55 |
| ELI LILLY & CO | 3.51 |
| MEDTRONIC PLC | 3.35 |
| ASTRAZENECA PLC | 3.30 |
| ABBOTT LABORATORIES | 3.22 |

## Geographic Allocation (% of Total)

| | Fund | Target |
|---|---|---|
| United States | 69.78 | 70.42 |
| Japan | 5.36 | 5.37 |
| United Kingdom | 4.21 | 4.22 |
| Denmark | 3.68 | 3.68 |
| France | 3.43 | 3.43 |
| Germany | 3.37 | 2.83 |
| Australia | 2.99 | 2.99 |
| Switzerland | 1.86 | 1.86 |
| Others | 5.18 | 5.19 |
| Cash & Cash Equivalents | 0.14 | 0.00 |

## Sector Allocation (% of Total)

| | Fund |
|---|---|
| Health Care Equipment | 30.18 |
| Pharmaceuticals | 24.28 |
| Biotechnology | 13.75 |
| Health Care Facilities | 7.93 |
| Health Care Technology | 3.19 |
| Consumer Electronics | 2.87 |
| Health Care Services | 2.41 |
| Life Sciences Tools & Services | 2.15 |
| Other | 13.11 |
| Cash & Cash Equivalents | 0.14 |

## Market Cap Breakdown (% of Equity) (USD)

| | Fund |
|---|---|
| <2.0 Billion | 13.57 |
| 2.0-5.0 Billion | 6.83 |
| 5.0-10.0 Billion | 7.18 |
| 10.0-25.0 Billion | 9.03 |
| 25.0-50.0 Billion | 10.17 |
| >50.0 Billion | 53.21 |

## Trading Information

| Exchange | Ticker | Currency | Bloomberg | Reuters | SEDOL |
|---|---|---|---|---|---|
| Borsa Italiana | FOHW | EUR | FOHW IM | FOHW.MI | BMCJZ47 |
| Deutsche Börse Xetra | FOHW | EUR | FOHW GR | FOHW.DE | BMCJZ36 |
| Euronext Paris Exchange | FOHW | EUR | FOHW FP | FOHW.PA | BSLMY42 |
| London Stock Exchange | FRHW | GBP | FRHW LN | FRHW.L | BMCJZ81 |
| London Stock Exchange | FOHW | USD | FOHW LN | FOHW.L | BMCJZ70 |
| SIX Swiss Exchange | FOHW | USD | FOHW SW | FOHW.S | BMCJZ58 |

## Portfolio Management

| | Years with Firm | Years of Experience |
|---|---|---|
| Dina Ting, CFA | 10 | 30 |
| Lorenzo Crosato, CFA | 9 | 27 |
| David McGowan, CFA | 5 | 13 |

## What are the Risks?

The Fund does not offer any capital guarantee or protection and you may not get back the amount invested. The Fund is subject to the following risks which are materially relevant: **Concentration risk:** the risk that arises when a fund invests in relatively few holdings, few sectors or a restricted geographic area. Performance may be more volatile than a fund with a greater number of securities. **Counterparty risk:** the risk of failure of financial institutions or agents (when serving as a counterparty to financial contracts) to perform their obligations, whether due to insolvency, bankruptcy or other causes. **Derivative Instruments risk:** the risk of loss in an instrument where a small change in the value of the underlying investment may have a larger impact on the value of such instrument. Derivatives may involve additional liquidity, credit and counterparty risks. **Foreign Currency risk:** the risk of loss arising from exchange-rate fluctuations or due to exchange control regulations. **Index related risk**: the risk that quantitative techniques used in creating the Index the Fund seeks to track do not generate the intended result, or that the portfolio of the Fund deviates from its Index composition or performance. **Secondary market trading risk:** the risk that the shares purchased on the secondary market cannot usually be sold directly back to the Fund and that investors may therefore pay more than the NAV per share when buying shares or may receive less than the current NAV per Share when selling shares.
Complete information on the risks of investing in the Fund are set out in the Fund's prospectus.

## Glossary

**Total Expense Ratio:** Total Expense Ratio (TER) includes the fees paid to the management company, the investment manager and the depository, as well as certain other expenses. The TER is calculated by taking the relevant main material costs paid out over the 12-month period indicated and dividing them by the average net assets over the same period. The TER does not include all expenses paid by the fund (for example, it does not include what the fund pays for buying and selling securities). For a comprehensive list of the types of costs deducted from fund assets, see the prospectus. For recent all-in annual costs, as well as hypothetical performance scenarios that show the effects that different levels of return could have on an investment in the fund, where applicable, see the KID. **Product Structure:** The Product Structure indicates whether an ETF is holding physical securities (i.e. Physical) or whether it is tracking the index performance using derivatives (swaps, i.e. Synthetic). **Methodology:** The Methodology indicates whether an ETF is holding all index securities in the same weight as the index (i.e. Physical Replication) or whether an optimised subset of index securities is used (i.e. Optimised) in order to efficiently track index performance. **Target:** The benchmark is defined in the objective as a target the Fund intends to meet or beat. **Price to Book:** The price per share of a stock divided by its book value (i.e., net worth) per share. For a portfolio, the value represents a weighted average of the stocks it holds. **Price to Earnings (12-Month Trailing)** is the share price of a stock, divided by its per-share earnings over the past year. For a portfolio, the value represents a weighted average of the stocks it holds. **Return on Equity:** A measure of a corporation's profitability that reveals how much profit a company generates with the money shareholders have invested. For a portfolio, the value represents a weighted average of the stocks it holds. **Dividend Yield** is the annual dividend received on an equity security as a percentage of the price. For a portfolio, the value represents a weighted average of the stocks it holds. It should not be used as an indication of the income received from this portfolio. **Dividend Yield is calculated without the deduction of fees and expenses.** **Standard Deviation:** Measure of the degree to which a fund's return varies from the average of its previous returns. The larger the standard deviation, the greater the likelihood (and risk) that a fund's performance will fluctuate from the average return.

## Portfolio Data Information

Holdings are provided for information purposes only and should not be deemed a recommendation to buy or sell the securities mentioned.

## Important Information

**This fund meets the requirements under Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR); the fund has binding commitments in its investment policy to promote environmental and/or social characteristics and any companies in which it invests should follow good governance practices.**
Further information in relation to the sustainability-related aspects of the Fund can be found at www.franklintempleton.lu/SFDR. Please review all of the Fund's objectives and characteristics before investing.

This material is intended to be of general interest only and should not be construed as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy. It does not constitute legal or tax advice. Special risks are associated with foreign investing, including currency fluctuations, economic instability and political developments; investments in emerging markets involve heightened risks related to the same factors. To the extent the fund focuses on particular countries, regions, industries, sectors or types of investment from time to time, it may be subject to greater risks of adverse developments in such areas at focus than a fund that invests in a wider variety of countries, regions, industries, sectors or investments. For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the Fund and will not be investing directly in the underlying assets of the Fund.
Franklin Templeton ICAV ("the ETF" or "Fund") investment returns and principal values will change with market conditions, and an investor may have a gain or a loss when they sell their shares. Please visit www.franklintempleton.com/corporate/all-sites for the Franklin Templeton ICAV standardised and most recent month-end performance. There is no guarantee that any strategy will achieve its objective.
All performance data shown is in the fund's base currency. Performance data is based on the net asset value (NAV) of the ETF which may not be the same as the market price of the ETF. Individual investors may realise returns that are different to the NAV performance. **Past performance does not predict future returns**. The actual costs vary depending on the executing custodian. In addition, deposit costs may be incurred which could have a negative effect on the value. Please find out the costs due from the respective price lists from the processing/custodian bank. Changes in exchange rates could have positive or negative effects on this investment. Please visit www.franklintempleton.com/corporate/all-sites to be directed to your local Franklin Templeton website for current performance, and to see the latest Prospectus or Supplement for further details. Information is historical and may not reflect current or future portfolio characteristics. All portfolio holdings are subject to change.
The Fund may use financial derivatives or other instruments which entail specific risks more fully described in the Fund's Documents. An investment in the ETF entails risks which are described in the latest Prospectus or Supplement and in the relevant KID. The Fund's documents are available in English, German and French from your local website or can be requested via FT's European Facilities Service which is available at www.eifs.lu/franklintempleton.
In addition, a Summary of Investor Rights is available from www.franklintempleton.lu/summary-of-investor-rights. The summary is available in English.
Franklin Templeton ICAV is notified for marketing in multiple EU Member States under the UCITS Directive. Franklin Templeton ICAV can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.
Franklin Templeton ICAV (domiciled outside of the U.S. or Canada) may not be directly or indirectly offered or sold to residents of the United States of America or Canada. ETFs trade like stocks, fluctuate in market value and may trade at prices above or below the ETFs net asset value. Brokerage commissions and ETF expenses will reduce returns.
Issued by Franklin Templeton International Services S.à r.l. – Supervised by the Commission de Surveillance du Secteur Financier – 8A, rue Albert Borschette, L-1246 Luxembourg.

**Benchmark(s)** Solactive Sustainable Health and Wellness Index-NR. Used for index tracking only.
The Fund is passively managed and seeks to replicate the benchmark by holding all of the Index securities in a similar proportion to their weighting in the benchmark. Its portfolio, and thus its performance, closely resemble that of the benchmark.

**Intended retail Investor** Investors who understand the risks of the Fund and plan to invest for at least 3 to 5 years. The Fund may appeal to investors who are looking for long-term investment growth, are interested in a thematic exposure to equity markets as part of a diversified portfolio, have a high risk profile and can tolerate significant short-term changes in the share price.
**Product availability** The Fund is available to all investors with at least basic investment knowledge, through a wide range of distribution channels, with or without the need for advice.
**CFA®** and Chartered Financial Analyst® are trademarks owned by CFA Institute.
**© Morningstar, Inc.** All rights reserved. The information contained here in (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Solactive AG ("Solactive") is the licensor of Solactive Sustainable Health and Wellness Index-NR (the "Index"). The financial instruments that are based on the Index are not sponsored, endorsed, promoted or sold by Solactive in any way and Solactive makes no express or implied representation, guarantee or assurance with regard to: (a) the advisability in investing in the financial instruments; (b) the quality, accuracy and/or completeness of the Index; and/or (c) the results obtained or to be obtained by any person or entity from the use of the Index. Solactive does not guarantee the accuracy and/or the completeness of the Index and shall not have any liability for any errors or omissions with respect thereto. Notwithstanding Solactive's obligations to its licensees, Solactive reserves the right to change the methods of calculation or publication with respect to the Index and Solactive shall not be liable for any miscalculation of or any incorrect, delayed or interrupted publication with respect to the Index. Solactive shall not be liable for any damages, including, without limitation, any loss of profits or business, or any special, incidental, punitive, indirect or consequential damages suffered or incurred as a result of the use (or inability to use) of the Index. Net Returns (NR) include income net of tax withholding when dividends are paid. Indices are unmanaged, and one cannot invest directly in an index. They do not reflect any fees, expenses or sales charges. Important data provider notices and terms available at www.franklintempletondatasources.com.
**In Europe** (excluding Switzerland), this financial promotion is issued by Franklin Templeton International Services S.à r.l. - Supervised by the Commission de Surveillance du Secteur Financier - 8A, rue Albert Borschette, L-1246 Luxembourg - Tel: +352-46 66 67-1 - Fax: +352 342080 9861. **In Switzerland,** issued by Franklin Templeton Switzerland Ltd, Talstrasse 41, CH-8001 Zurich. Paying agent in Switzerland is BNP Paribas Securities Services, Paris, succursale de Zurich, Selnaustrasse16, 8002 Zurich.
© 2026 Franklin Templeton. All rights reserved.